Pacira BioSciences (NASDAQ:PCRX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Pacira BioSciences (NASDAQ:PCRX) had its target price boosted by equities research analysts at HC Wainwright from $57.00 to $70.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 191.06% from the company’s current price.

Several other brokerages have also weighed in on PCRX. Barclays reduced their price objective on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a report on Tuesday, November 12th. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. Needham & Company LLC increased their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price target for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $27.22.

Pacira BioSciences Stock Down 5.2 %

PCRX opened at $24.05 on Friday. The company’s 50-day moving average price is $23.16 and its two-hundred day moving average price is $18.63. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $31.67. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -11.85 and a beta of 0.80.

Institutional Trading of Pacira BioSciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its position in shares of Pacira BioSciences by 62.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock valued at $134,000 after purchasing an additional 3,404 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in Pacira BioSciences during the third quarter valued at $793,000. Robeco Institutional Asset Management B.V. purchased a new position in Pacira BioSciences during the third quarter worth about $1,053,000. Impax Asset Management Group plc increased its stake in Pacira BioSciences by 81.0% in the 3rd quarter. Impax Asset Management Group plc now owns 470,603 shares of the company’s stock worth $7,083,000 after acquiring an additional 210,576 shares during the last quarter. Finally, Easterly Investment Partners LLC raised its holdings in shares of Pacira BioSciences by 27.4% in the 3rd quarter. Easterly Investment Partners LLC now owns 134,484 shares of the company’s stock valued at $2,024,000 after acquiring an additional 28,928 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.